133 related articles for article (PubMed ID: 23385202)
1. Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis.
Salinas C; Weinzimmer D; Searle G; Labaree D; Ropchan J; Huang Y; Rabiner EA; Carson RE; Gunn RN
J Cereb Blood Flow Metab; 2013 May; 33(5):700-7. PubMed ID: 23385202
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon.
Logan J; Carruthers NI; Letavic MA; Sands S; Jiang X; Shea C; Muench L; Xu Y; Carter P; King P; Fowler JS
Psychopharmacology (Berl); 2012 Oct; 223(4):447-55. PubMed ID: 22614669
[TBL] [Abstract][Full Text] [Related]
3. Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.
Ashworth S; Berges A; Rabiner EA; Wilson AA; Comley RA; Lai RY; Boardley R; Searle G; Gunn RN; Laruelle M; Cunningham VJ
Br J Pharmacol; 2014 Mar; 171(5):1241-9. PubMed ID: 24670146
[TBL] [Abstract][Full Text] [Related]
4. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects.
Jucaite A; Takano A; Boström E; Jostell KG; Stenkrona P; Halldin C; Segerdahl M; Nyberg S
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1231-9. PubMed ID: 23217964
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET.
Ashworth S; Rabiner EA; Gunn RN; Plisson C; Wilson AA; Comley RA; Lai RY; Gee AD; Laruelle M; Cunningham VJ
J Nucl Med; 2010 Jul; 51(7):1021-9. PubMed ID: 20554726
[TBL] [Abstract][Full Text] [Related]
6. Determination of receptor occupancy in the presence of mass dose: [
Gallezot JD; Planeta B; Nabulsi N; Palumbo D; Li X; Liu J; Rowinski C; Chidsey K; Labaree D; Ropchan J; Lin SF; Sawant-Basak A; McCarthy TJ; Schmidt AW; Huang Y; Carson RE
J Cereb Blood Flow Metab; 2017 Mar; 37(3):1095-1107. PubMed ID: 27207170
[TBL] [Abstract][Full Text] [Related]
7. 11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET.
Plisson C; Gunn RN; Cunningham VJ; Bender D; Salinas CA; Medhurst AD; Roberts JC; Laruelle M; Gee AD
J Nucl Med; 2009 Dec; 50(12):2064-72. PubMed ID: 19910432
[TBL] [Abstract][Full Text] [Related]
8. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic assessment of histamine H
Kimura Y; Takahata K; Shimazaki T; Kitamura S; Seki C; Ikoma Y; Ichise M; Kawamura K; Yamada M; Zhang MR; Higuchi M; Nishino I; Suhara T
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1127-1135. PubMed ID: 34651222
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Modeling of [
Ghazanfari N; van Waarde A; Doorduin J; Sijbesma JWA; Kominia M; Koelewijn M; Attia K; Willemsen ATM; Visser TJ; Heeres A; Dierckx RAJO; de Vries EFJ; Elsinga PH
Mol Pharm; 2022 Mar; 19(3):918-928. PubMed ID: 35170965
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
Guo RX; Anaclet C; Roberts JC; Parmentier R; Zhang M; Guidon G; Buda C; Sastre JP; Feng JQ; Franco P; Brown SH; Upton N; Medhurst AD; Lin JS
Br J Pharmacol; 2009 May; 157(1):104-17. PubMed ID: 19413575
[TBL] [Abstract][Full Text] [Related]
12. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats.
Giannoni P; Medhurst AD; Passani MB; Giovannini MG; Ballini C; Corte LD; Blandina P
J Pharmacol Exp Ther; 2010 Jan; 332(1):164-72. PubMed ID: 19815811
[TBL] [Abstract][Full Text] [Related]
13. Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Brackenborough K; Briggs MA; Brough S; Calver AR; Crook B; Davis RK; Davis RP; Davis S; Dean DK; Harris L; Heslop T; Holland V; Jeffrey P; Panchal TA; Parr CA; Quashie N; Schogger J; Sehmi SS; Stean TO; Steadman JG; Trail B; Wald J; Worby A; Takle AK; Witherington J; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6890-6. PubMed ID: 24269482
[TBL] [Abstract][Full Text] [Related]
14. Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.
Medhurst AD; Roberts JC; Lee J; Chen CP; Brown SH; Roman S; Lai MK
Br J Pharmacol; 2009 May; 157(1):130-8. PubMed ID: 19222483
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems.
Hsieh GC; Honore P; Pai M; Wensink EJ; Chandran P; Salyers AK; Wetter JM; Zhao C; Liu H; Decker MW; Esbenshade TA; Cowart MD; Brioni JD
Brain Res; 2010 Oct; 1354():74-84. PubMed ID: 20682302
[TBL] [Abstract][Full Text] [Related]
16. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H
Riddy DM; Cook AE; Shackleford DM; Pierce TL; Mocaer E; Mannoury la Cour C; Sors A; Charman WN; Summers RJ; Sexton PM; Christopoulos A; Langmead CJ
Neuropharmacology; 2019 Jan; 144():244-255. PubMed ID: 30359639
[TBL] [Abstract][Full Text] [Related]
17. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
[TBL] [Abstract][Full Text] [Related]
18. H3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms.
Foley AG; Prendergast A; Barry C; Scully D; Upton N; Medhurst AD; Regan CM
Neuropsychopharmacology; 2009 Nov; 34(12):2585-600. PubMed ID: 19657331
[TBL] [Abstract][Full Text] [Related]
19. In vivo receptor occupancy assay of histamine H₃ receptor antagonist in rats using non-radiolabeled tracer.
Nirogi R; Kandikere V; Bhyrapuneni G; Muddana N; Saralaya R; Ponnamaneni RK; Manoharan AK
J Pharmacol Toxicol Methods; 2012; 65(3):115-21. PubMed ID: 22487318
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography.
Borroni E; Zhou Y; Ostrowitzki S; Alberati D; Kumar A; Hainzl D; Hartung T; Hilton J; Dannals RF; Wong DF
Neuroimage; 2013 Jul; 75():291-300. PubMed ID: 22178811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
